Soligenix Inc.https://investorshangout.com/Soligenix-Inc-SNGX-91975/en-usWed, 02 Sep 2026 15:49:00 GMTCopyright InvestorsHangout.comNetworkNewsWire: NetworkNewsBreaks – Soligenix Inc. (NASDAQ: SNGX) CEO Highlights Capital Discipline as Critical thttps://investorshangout.com/post/view?id=6825696https://investorshangout.com/post/view?id=6825696Tue, 21 Apr 2026 20:34:34 GMTNetworkNewsWire: Soligenix Inc. (NASDAQ: SNGX) Strengthens Pipeline as European Commission Grants SGX945 Orphan Sthttps://investorshangout.com/post/view?id=6824927https://investorshangout.com/post/view?id=6824927Fri, 17 Apr 2026 20:46:44 GMTNetworkNewsWire: Soligenix Inc. (NASDAQ: SNGX) Advances CTCL Research with Interim Analysis, Comparative Study Reshttps://investorshangout.com/post/view?id=6824695https://investorshangout.com/post/view?id=6824695Thu, 16 Apr 2026 21:16:19 GMTNetworkNewsWire: Soligenix Inc. (NASDAQ: SNGX) Gains Analytical Validation as Pipeline Progress Drives Forward Outhttps://investorshangout.com/post/view?id=6824496https://investorshangout.com/post/view?id=6824496Wed, 15 Apr 2026 20:55:04 GMTNetworkNewsWire: NetworkNewsBreaks – Soligenix Inc. (NASDAQ: SNGX) Showcased for Smarter Path to Drug Development https://investorshangout.com/post/view?id=6824300https://investorshangout.com/post/view?id=6824300Tue, 14 Apr 2026 20:27:46 GMTNetworkNewsWire: NetworkNewsBreaks – Soligenix Inc. (NASDAQ: SNGX) Publishes Positive HyBryte Study Results In Onchttps://investorshangout.com/post/view?id=6822777https://investorshangout.com/post/view?id=6822777Thu, 02 Apr 2026 21:12:37 GMTNetworkNewsWire: Soligenix Inc. (NASDAQ: SNGX) Advances Clinical Credibility with HyBryte Research Publicationhttps://investorshangout.com/post/view?id=6822643https://investorshangout.com/post/view?id=6822643Wed, 01 Apr 2026 21:02:07 GMTNetworkNewsWire: Soligenix Inc. (NASDAQ: SNGX) Expands Pipeline Momentum as SGX945 Earns Global Recognition https://investorshangout.com/post/view?id=6822445https://investorshangout.com/post/view?id=6822445Tue, 31 Mar 2026 20:27:04 GMTNetworkNewsWire: NetworkNewsBreaks – Soligenix Inc. (NASDAQ: SNGX) Highlights Phase 3 CTCL Progress and Orphan Druhttps://investorshangout.com/post/view?id=6822440https://investorshangout.com/post/view?id=6822440Tue, 31 Mar 2026 20:16:22 GMTNetworkNewsWire: NetworkNewsBreaks – Soligenix Inc. (NASDAQ: SNGX) Receives EU Orphan Drug Designation For Dusquethttps://investorshangout.com/post/view?id=6821774https://investorshangout.com/post/view?id=6821774Thu, 26 Mar 2026 20:52:03 GMTNetworkNewsWire: Soligenix Inc. (NASDAQ: SNGX) Spotlighted in Recent Zacks Research Report as Key Clinical Milestohttps://investorshangout.com/post/view?id=6821384https://investorshangout.com/post/view?id=6821384Tue, 24 Mar 2026 21:21:46 GMTNetworkNewsWire: NetworkNewsBreaks – Soligenix Inc. (NASDAQ: SNGX) HyBryte Data To Be Presented At USCLC Workshop https://investorshangout.com/post/view?id=6821164https://investorshangout.com/post/view?id=6821164Mon, 23 Mar 2026 21:04:16 GMTNetworkNewsWire: NetworkNewsBreaks – Soligenix Inc. (NASDAQ: SNGX) Advances Orphan Drug Strategy With HyBryte In Rhttps://investorshangout.com/post/view?id=6821160https://investorshangout.com/post/view?id=6821160Mon, 23 Mar 2026 20:57:51 GMTNetworkNewsWire: Soligenix Inc. (NASDAQ: SNGX) Strengthens Rare Disease Pipeline Program Through UK Regulatory Innhttps://investorshangout.com/post/view?id=6820892https://investorshangout.com/post/view?id=6820892Fri, 20 Mar 2026 21:00:07 GMTNetworkNewsWire: NetworkNewsBreaks – Soligenix Inc. (NASDAQ: SNGX) Featured On BioMedWire Podcast Highlighting Phahttps://investorshangout.com/post/view?id=6820716https://investorshangout.com/post/view?id=6820716Thu, 19 Mar 2026 21:16:29 GMTNetworkNewsWire: NetworkNewsBreaks – Soligenix Inc. (NASDAQ: SNGX) Highlights HyBryte Clinical Data In Peer-Reviewhttps://investorshangout.com/post/view?id=6820715https://investorshangout.com/post/view?id=6820715Thu, 19 Mar 2026 21:14:10 GMTNetworkNewsWire: Soligenix Inc. (NASDAQ: SNGX) Advances Rare Disease Innovation Through Platform Science and Expanhttps://investorshangout.com/post/view?id=6820554https://investorshangout.com/post/view?id=6820554Wed, 18 Mar 2026 20:22:41 GMTNetworkNewsWire: NetworkNewsBreaks – Soligenix Inc. (NASDAQ: SNGX) SGX945 Granted Promising Innovative Medicine Dehttps://investorshangout.com/post/view?id=6819376https://investorshangout.com/post/view?id=6819376Tue, 10 Mar 2026 20:53:51 GMTNetworkNewsWire: Soligenix Inc. (NASDAQ: SNGX) Secures Key European Milestone for Dusquetide Development - https://investorshangout.com/post/view?id=6819175https://investorshangout.com/post/view?id=6819175Mon, 09 Mar 2026 21:08:30 GMTNetworkNewsWire: Soligenix Inc. (NASDAQ: SNGX) Leverages Platform Science for Broader Therapeutic Reach - Phttps://investorshangout.com/post/view?id=6818610https://investorshangout.com/post/view?id=6818610Thu, 05 Mar 2026 21:43:37 GMTNetworkNewsWire: NetworkNewsBreaks – Soligenix Inc. (NASDAQ: SNGX) Receives Positive EMA Orphan Drug Opinion for Dhttps://investorshangout.com/post/view?id=6817412https://investorshangout.com/post/view?id=6817412Thu, 26 Feb 2026 22:34:07 GMTNetworkNewsWire: NetworkNewsBreaks – Soligenix Inc. (NASDAQ: SNGX) CEO to Present at BIO Investment & Growth Summihttps://investorshangout.com/post/view?id=6817130https://investorshangout.com/post/view?id=6817130Tue, 24 Feb 2026 21:16:23 GMTNetworkNewsWire: NetworkNewsBreaks – Soligenix Inc. (NASDAQ: SNGX) CEO Highlights 2026 Clinical Milestones and Strhttps://investorshangout.com/post/view?id=6815539https://investorshangout.com/post/view?id=6815539Thu, 12 Feb 2026 21:50:46 GMTNetworkNewsWire: Soligenix Inc. (NASDAQ: SNGX) Driving Innovation in Photodynamic Therapy Potential in Oncology, Dhttps://investorshangout.com/post/view?id=6815155https://investorshangout.com/post/view?id=6815155Tue, 10 Feb 2026 22:30:03 GMTNetworkNewsWire: NetworkNewsBreaks – Soligenix Inc.’s (NASDAQ: SNGX) SGX945 Shows Promise with Immune-Modulating Ahttps://investorshangout.com/post/view?id=6814697https://investorshangout.com/post/view?id=6814697Fri, 06 Feb 2026 22:26:29 GMTNetworkNewsWire: Soligenix Inc. (NASDAQ: SNGX) Builds Momentum in Fight Against Rare, Chronic Cancer - Althhttps://investorshangout.com/post/view?id=6814031https://investorshangout.com/post/view?id=6814031Mon, 02 Feb 2026 21:51:15 GMTNetworkNewsWire: Soligenix (NASDAQ: SNGX) Positioning for Impact in Growing Rare-Disease Landscape - The Wohttps://investorshangout.com/post/view?id=6813656https://investorshangout.com/post/view?id=6813656Fri, 30 Jan 2026 21:34:25 GMTNetworkNewsWire: NetworkNewsBreaks – Soligenix Inc. (NASDAQ: SNGX) Targets Critical Gaps in CTCL Treatment with Hyhttps://investorshangout.com/post/view?id=6813485https://investorshangout.com/post/view?id=6813485Thu, 29 Jan 2026 20:54:40 GMTNetworkNewsWire: Meta Analysis Finds That Weight Reduction Reduces Severity of Psoriasis Psoriasis is a chrhttps://investorshangout.com/post/view?id=6812545https://investorshangout.com/post/view?id=6812545Fri, 23 Jan 2026 23:04:58 GMTNetworkNewsWire: NetworkNewsBreaks – RiVax(R) Positions Soligenix Inc. (NASDAQ: SNGX) in Growing Biodefense Preparhttps://investorshangout.com/post/view?id=6812536https://investorshangout.com/post/view?id=6812536Fri, 23 Jan 2026 22:30:47 GMTNetworkNewsWire: Soligenix Inc. (NASDAQ: SNGX) Announces Positive Phase 2 Data for Rare Inflammatory Disease https://investorshangout.com/post/view?id=6811999https://investorshangout.com/post/view?id=6811999Tue, 20 Jan 2026 22:02:41 GMTNetworkNewsWire: Soligenix Inc. (NASDAQ: SNGX) Announces Positive Phase 2 Data for Rare Inflammatory Disease https://investorshangout.com/post/view?id=6811604https://investorshangout.com/post/view?id=6811604Fri, 16 Jan 2026 20:31:51 GMTNetworkNewsWire: Michigan State University Research Says Suppressing Postoperative Pain Could Delay Healing https://investorshangout.com/post/view?id=6811416https://investorshangout.com/post/view?id=6811416Thu, 15 Jan 2026 21:35:54 GMTNetworkNewsWire: Soligenix Inc. (NASDAQ: SNGX) Advances Solutions for Hard-to-Diagnose CTCL - CTCL is recoghttps://investorshangout.com/post/view?id=6811190https://investorshangout.com/post/view?id=6811190Wed, 14 Jan 2026 21:07:14 GMTNetworkNewsWire: NetworkNewsBreaks – Soligenix Inc. (NASDAQ: SNGX) Reaches Enrollment Milestone in Phase 3 FLASH2 https://investorshangout.com/post/view?id=6810454https://investorshangout.com/post/view?id=6810454Fri, 09 Jan 2026 22:08:42 GMTNetworkNewsWire: The WHO Highlights Successes, Challenges to Global Health The World Health Organization (Whttps://investorshangout.com/post/view?id=6809650https://investorshangout.com/post/view?id=6809650Mon, 05 Jan 2026 21:49:05 GMTNetworkNewsWire: Soligenix Inc. (NASDAQ: SNGX) Extends SGX302 Clinical Success in Phase 2A Psoriasis Study https://investorshangout.com/post/view?id=6808175https://investorshangout.com/post/view?id=6808175Mon, 22 Dec 2025 21:21:15 GMTNetworkNewsWire: Soligenix Inc. (NASDAQ: SNGX) Advances Ricin Vaccine amid Toxin Threat - A recent report fhttps://investorshangout.com/post/view?id=6807922https://investorshangout.com/post/view?id=6807922Fri, 19 Dec 2025 22:30:57 GMTNetworkNewsWire: Chronic Inflammation Could Be the Missing Key to Understanding Long Covid In the U.S. abouhttps://investorshangout.com/post/view?id=6807725https://investorshangout.com/post/view?id=6807725Thu, 18 Dec 2025 22:23:41 GMTNetworkNewsWire: NetworkNewsBreaks – Soligenix Inc. (NASDAQ: SNGX) Publishes Positive Phase 2a SGX945 Data in Behçhttps://investorshangout.com/post/view?id=6807717https://investorshangout.com/post/view?id=6807717Thu, 18 Dec 2025 21:50:58 GMTNetworkNewsWire: NetworkNewsBreaks – Soligenix Inc. (NASDAQ: SNGX) Reports Extended Phase 2a Results for SGX302 Gehttps://investorshangout.com/post/view?id=6807496https://investorshangout.com/post/view?id=6807496Wed, 17 Dec 2025 21:38:40 GMTNetworkNewsWire: NetworkNewsBreaks – Soligenix Inc. (NASDAQ: SNGX) Featured in NetworkNewsAudio APR on Urgent Needhttps://investorshangout.com/post/view?id=6806274https://investorshangout.com/post/view?id=6806274Wed, 10 Dec 2025 20:09:32 GMTNetworkNewsWire: US to End Mandatory Vaccination of Newborns Against Hepatitis B Since 1991, there has exishttps://investorshangout.com/post/view?id=6806066https://investorshangout.com/post/view?id=6806066Tue, 09 Dec 2025 21:58:17 GMTNetworkNewsWire: Soligenix Inc. (NASDAQ: SNGX) Receives Strong Vote of Confidence from Zacks Report Despite Muted https://investorshangout.com/post/view?id=6805833https://investorshangout.com/post/view?id=6805833Mon, 08 Dec 2025 21:59:23 GMTNetworkNewsWire: NetworkNewsBreaks – Soligenix Inc. (NASDAQ: SNGX) Featured in BioMedWire Editorial on Rare Diseashttps://investorshangout.com/post/view?id=6805507https://investorshangout.com/post/view?id=6805507Fri, 05 Dec 2025 21:47:17 GMTNetworkNewsWire: NetworkNewsBreaks – Soligenix Inc. (NASDAQ: SNGX) Featured in BioMedWire Editorial Highlighting Hhttps://investorshangout.com/post/view?id=6805073https://investorshangout.com/post/view?id=6805073Wed, 03 Dec 2025 20:23:37 GMTNetworkNewsWire: Study Uncovers Surprising Connection Between Choline, Obesity and Brain Inflammation For ahttps://investorshangout.com/post/view?id=6804604https://investorshangout.com/post/view?id=6804604Mon, 01 Dec 2025 22:17:51 GMTNetworkNewsWire: Soligenix Inc. (NASDAQ: SNGX) Reaches Key Enrollment Milestone in Phase 3 Trial with Encouraging https://investorshangout.com/post/view?id=6804602https://investorshangout.com/post/view?id=6804602Mon, 01 Dec 2025 22:11:03 GMTNetworkNewsWire: Soligenix Inc. (NASDAQ: SNGX) Strengthens CTCL Program as DMC Flags No Safety Issues - Thihttps://investorshangout.com/post/view?id=6803604https://investorshangout.com/post/view?id=6803604Mon, 24 Nov 2025 20:25:30 GMTNetworkNewsWire: NetworkNewsBreaks – Soligenix Inc. (NASDAQ: SNGX) Completes Enrollment for Interim Analysis in Phhttps://investorshangout.com/post/view?id=6802889https://investorshangout.com/post/view?id=6802889Wed, 19 Nov 2025 21:48:59 GMT